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Abstract
Background/Aim. Long-term intensive training is associ-
ated with distinctive cardiac adaptations which are known as
athlete’s heart. The aim of this study was to determine
whether the use of anabolic androgenic steroids (AAS)
could affect echocardiographic parameters of left ventricu-
lar (LV) morphology and function in elite strength and en-
durance athletes. Methods. A total of 20 elite strength ath-
letes (10 AAS users and 10 non-users) were compared to 12
steroid-free endurance athletes. All the subjects underwent
comprehensive standard echocardiography and tissue Dop-
pler imaging. Results. After being indexed for body surface
area, both left atrium (LA) and LV end-diastolic diameter
(LVEDD) were significantly higher in the endurance than
strength athletes, regardless of AAS use (p < 0.05, for both).
A significant correlation was found between LA diameter
and LVEDD in the steroid-free endurance athletes, show-
ing that 75% of LA size variability depends on variability of
LVEDD (p < 0.001). No significant differences in ejection
fraction and cardiac output were observed among the
groups, although mildly reduced LV ejection fraction was
seen only in the AAS users. The AAS-using strength ath-
letes had higher A-peak velocity when compared to steroid-
free athletes, regardless of training type (p < 0.05 for both).
Both AAS-using and AAS-free strength athletes had lower
e’ peak velocity and higher E/e’ ratio than endurance ath-
letes (p < 0.05, for all). Conclusions. There is no evidence
that LV ejection fraction in elite athletes is altered by either
type of training or AAS misuse. Long-term endurance
training is associated with preferable effects on LV diastolic
function compared to strength training, particularly when
the latter is combined with AAS abuse.
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Apstrakt
Uvod/Cilj. Dugotrajni intenzivni trening povezan je sa
adaptivnim promenama srÿanog mišiýa poznatim kao sport-
sko srce. Cilj rada bio je da se utvrdi uticaj primene anaboli-
ÿkih androgenih steroida (AAS) na ehokardiografske para-
metre morfologije i funkcije leve komore (LV) kod elitnih
sportista koji se bave sportovima snage i izdržljivosti. Me-
tode. Dvadeset elitnih sportista snage (10 korisnika AAS i
10 onih koji ne koriste AAS) uporeĀeni su sa 12 sportista
izdržljivosti koji ne koriste AAS. Svi ispitanici bili su podvr-
gnuti standardnom ehokardiografskom pregledu sa tkivnim
Dopler-om. Rezultati. Nakon indeksiranja prema telesnoj
površini, leva pretkomora (LA) i end-dijastolni preÿnik leve
komore (LVEDD) bili su znaÿajno veýi kod sportista izdrž-
ljivosti nego kod sportista snage, bez obzira na uzimanje
AAS (p < 0,05, za oba). NaĀena je znaÿajna korelacija izme-
Āu veliÿine LA i LVEDD kod sportista izdržljivosti koji ne
uzimaju AAS, koja pokazuje da 75% varijablnosti veliÿine
LA zavisi od varijabilnosti LVEDD (p < 0,001). Nije poka-
zana znaÿajna razlika u ejekcionoj frakciji (EF) LV (LVEF) i
minutnom volumenu izmeĀu grupa, mada je blago snižena
LVEF viĀena samo kod sportista koji koriste AAS. Sportisti
snage koji koriste AAS imali su veýu vrednost pika A-talasa
u poreĀenju sa sportistima koji ne koriste AAS, bez obzira
na tip treninga (p < 0,05 za oba). Sportisti snage, bez obzira
na primenu AAS, imali su niže vrednosti brzine e’ talasa i
veýi E/e’ odnos u poreĀenju sa sportistima izdržljivosti
(p < 0,05 za sve). Zakljuÿak. Nema dokaza da je primena
AAS povezana sa promenom LVEF, bez obzira na tip tre-
ninga. Dugoroÿni trening izdržljivosti povezan je sa povolj-
nim efektima na dijastolnu funkciju LV u poreĀenju sa tre-
ningom snage, pogotovu ako je trening snage povezan sa
zloupotrebom AAS.
Kljuÿne reÿi:
sportisti; zloupotreba supstanci; androgeni; srce,
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Introduction
Long-term intensive training is associated with distinc-
tive cardiac adaptations which are known as athlete’s heart 
1.
Although a certain relationship between the type of training
(endurance versus strength exercise) and cardiac remodeling
has been documented, the nature and magnitude of training-
induced changes are still the subject of debate.
Anabolic androgenic steroids (AAS) have been abused
by both professional and recreational athletes to increase
muscle mass and improve performance 
2. The use of AAS is
particularly prevalent among powerlifters and bodybuilders –
as many as 55% of elite powerlifters admitted using these
agents 
3, 4. In contrast to numerous documented toxic and
hormonal effects of AAS, their impact on left ventricular
(LV) structure and function was not been yet completely un-
derstood. In animal model, AAS have been shown to induce
cardiac renin-angiotensin system, increase cardiac collagen
content and impair the beneficial effects of training 
5. In
competitive athletes, self-administration of AAS has been
linked to serious cardiac adverse events, including sudden
cardiac death 
6, 7, although reports on their impact on cardiac
morphology and function varied 
8.
We hypothesized that there would be the differences in
echocardiographic parameters of LV morphology and function
between strength and endurance athletes and that the magni-
tude of these differences would be affected by AAS abuse. To
test this hypothesis, we compared elite strength athletes using
or not using AAS to steroid-free endurance athletes.
Methods
A total of 22 elite male athletes, aged 22–40 years, were
recruited from the national power-lifting, bodybuilding,
wrestling and running clubs. All the subjects gave written in-
formed consent and were divided into three groups.
The group I consisted of 10 strength athletes (6 power-
lifters and 4 bodybuilders) who reported both past and cur-
rent self-administration of AAS. All the subjects used the
combination of oral and injectable substances (methandie-
none, stanozolol, nandrolone decanoate and testosterone) for
at least 3 years, in cycles lasting between 7 and 14 weeks.
The group II consisted of 10 strength athletes (4 bodybuild-
ers and 6 wrestlers) who denied taking AAS. They were all
negative on several doping tests during and out of competi-
tion. The group III consisted of 12 endurance athletes (long-
distance runners) who did not use AAS. They were also
negative on doping tests performed during professional ca-
reer. None of the subjects in either group had a history of
cardiovascular or any other organic system disorder and were
not taking any medications.
Anthropometric measurements
Body mass and height were measured using a balance
beam scale and a height gauge, respectively. Lean body mass
was calculated according to the formula provided by Hal-
lynck et al. 
9, whereas body surface area was calculated using
the Mosteller formula 
10.
Electrocardiography and blood pressure measurement
Twelve-channel electrocardiography (ECG) recording
was done prior to blood pressure measurement and echocar-
diographic examination.
Blood pressure measurements were done in sitting po-
sition, using a cuff adjusted to upper arm circumference. The
mean value of two measurements on both arms, 10 min
apart, was recorded.
Echocardiographic examination
All examinations were done in supine left decubitus po-
sition using a Hewlett–Packard Sonos 2500 machine (Ando-
ver, MA, USA), with a 2.5 MHz transducer. Echocardio-
grams consisted of two-dimensional, M-mode, Doppler flow
measurements and tissue Doppler imaging (TDI) from stan-
dard parasternal and apical positions. All measurements were
made by a single experienced observer (VD) who was
blinded to the subjects’ data.
M-mode measurements were performed for the assess-
ment of LV diastolic and systolic diameters, according to the
most recent guidelines 
11 and presented both as raw data and
adjusted for body surface area (BSA) when appropriate. Meas-
urements obtained with this method served for calculation of
LV mass, using the Devereux et al. formula 
12. Relative wall
thickness (RWT) was calculated when the sum of interven-
tricular septal wall (IVS) thickness and posterior wall (PW)
thickness was divided by LV end-diastolic diameter (LVEDD).
For the assessment of systolic function  LV volumes
were measured by tracing the endocardial border in apical
four- and two-chamber view. The ejection fraction was esti-
mated using the Simpson’s biplanar method 
11. Cardiac out-
put was determined by calculating the product of stroke vol-
ume and heart rate that was obtained from the final loop of
each study.
Pulsed-Doppler LV inflow recordings were made in the
apical four-chamber view, with the sample volume placed at
the tips level of the mitral valve. Early (E) and atrial (A) peak
velocities, E-wave deceleration time and isovolumetric relaxa-
tion time were measured. TDI recordings were performed in
apical four-chamber view, with the pulse-wave Dop-
pler sample volume placed at the septal and lateral side of mi-
tral annulus. Longitudinal tissue Doppler velocities of a sys-
tolic wave (S) and 2 diastolic waves – early (e’) and atrial (a’)
– were reported as the mean of 3 consecutive cardiac cycles.
Most recent guidelines on the chamber quantification and the
assessment of LV diastolic function were used to define a ref-
erence range for all echocardiographic parameters 
11, 13.
Statistical analysis
Data are expressed as mean ± standard deviation. Com-
parison between the groups was performed using the analysis
of variance or a Kruskal–Wallis test, with Bonferroni cor-
rection for multiple comparisons. The relations between se-
lected measures were calculated by the linear regression
analysis and correlation analysis using the Pearson or
Spearman’s method. A p-value of <  0.05 was considered
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Results
The athletes from the 3 groups were comparable for
age, body mass, BSA, lean body mass and duration of train-
ing (Table1).
Resting heart rate and diastolic blood pressure were
significantly lower in the endurance than the AAS-using
strength athletes, with no significant difference between
ASS-free athletes.
Standard echocardiographic parameters
The standard echocardiographic parameters are shown
in Table 2. No significant differences in wall thickness were
found among the 3 groups.
After being indexed for BSA, both left atrium (LA) di-
mension and LVEDD were higher in the endurance than
AAS-using strength athletes. Further, a significant correla-
tion between LA diameter and LVEDD was found, but only
in the endurance athletes, in whom more than 75% of LA
size variability (R
2  =  0.761) depended on variability of
LVEDD (Figure 1A). It was also shown for this group that
each increase of 1 mm in LVEDD was associated with ap-
proximately 0.7 mm increase in LA diameter (95% confi-
dence interval (CI) 0.44 to 1.01, p < 0.001). A trend towards
a significant correlation between LVEDD and LA diameter
was noted in the AAS-free strength athletes (Figure 1B),
while such correlation was not observed in the AAS-using
strength athletes (Figure 1C).
Table 1
Mean clinical characteristics of the study participants
Athletes type
Characteristics AAS-using
strength athletes
(n = 10), ʉ ± SD
AAS-free
strength athletes
(n = 10), ʉ ± SD
AAS-free
endurance athletes
(n = 12), ʉ ± SD
Age (yrs) 27 ± 6 29 ± 6 27 ± 4
Height (cm) 181 ± 5 179 ± 4 190 ± 11*
†
Body mass (kg) 100 ± 19 85 ± 18 87 ± 18
Body surface area (m
2) 2.2 ± 0.2 2.1 ± 0.2 2.1 ± 0.3
Lean body mass (kg) 69 ± 8 64 ± 8 69 ± 12
Heart rate (beats/min) 77 ± 16 68 ± 15 56 ± 8*
PR interval (ms) 150 ± 22 161 ± 25 174 ± 19*
Systolic BP (mmHg) 133 ± 23 128 ± 15 118 ± 12
Diastolic BP (mmHg) 88 ± 14 80 ± 11 71 ± 8*
Duration of training (yrs) 10.1 ± 3.0 13.4 ± 4.2 13.6 ± 2.8
Intensity of training (hrs/week) 11.6 ± 3.0 10.1 ± 3.4 20.8 ± 15.7
†
AAS – anabolic androgenic steroids; BP – blood pressure;
*significantly different from AAS-using strength athletes (p < 0.05);
†significantly different from AAS-free strength athletes (p < 0.05).
Table 2
M-mode and two-dimensional echocardiographic measurements in the study participants
Athletes type
Parameter AAS-using strength athletes
(n = 10), ʉ ± SD
AAS-free strength athletes
(n = 10), ʉ ± SD
AAS-free endurance athletes
(n = 12), ʉ ± SD
LVEDD (mm) 49.9 ± 4.8 52.2 ± 3.2 57.0 ± 3.9*
†
LVEDD per unit BSA (mm/m
2) 22.5 ± 3.0 25.7 ± 2.3 27.0 ± 3.3*
LA (mm) 34.2 ± 5.2 34.9 ± 1.9 39.3 ± 4.56*
LA per unit BSA (mm/m
2) 15.3 ± 2.3 17.2 ± 1.9 18.6 ± 2.7*
LV mass (g) 194 ± 44 180 ± 43 239 ± 58*
†
LV mass per unit BSA (g/m
2) 87 ± 16 88 ± 21 114 ± 33*
IVS thickness (mm) 10.7 ± 2.2 9.7 ± 1.2 10.7 ± 1.7
PW thickness (mm) 10.3 ± 2.1 8.9 ± 1.3 9.7 ± 1.4
Relative wall thickness 0.41 ± 0.12 0.35 ± 0.04 0.36 ± 0.06
AAS – anabolic androgenic steroids; BSA – body surface area; IVS – interventricular septum; LA – left atrium; LV – left ventricle; LVEDD – left ventricular
end-diastolic diameter; PW – posterior wall; *significantly different from AAS-using strength athletes (p < 0.05); 
†significantly different from AAS-free strength
athletes (p < 0.05).
Fig. 1 – Correlation between the left ventricular end-diastolic diameter (LVEDD) and left atrial size (LA), both indexed for
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Left ventricular systolic function
No significant differences in ejection fraction, cardiac
output and cardiac index were observed among the groups
(Table 3). However, 3 of the 10 AAS users had LV ejection
fraction below 55%, while all AAS-free athletes had normal
LV ejection fraction ( 55%). Peak systolic velocity (S) at
septal level was significantly higher in the endurance than
AAS-free strength athletes.
Transmitral Doppler velocities and tissue Doppler
Imaging data
The AAS-using strength athletes had higher peak A-
wave velocity when compared to both endurance and AAS-
free strength athletes (Table 3). Regardless of AAS misuse,
the strength athletes had significantly lower e’ peak velocity
and higher E/e’ ratio than the endurance athletes, when
measurements were done at lateral wall level (Table 3). Peak
e’ velocities at lateral wall level were within reference range
in all endurance athletes, while in 30% of AAS-using
strength athletes laid outside the normal range.
The 95% confidence itervals (CI) for the peak lateral e’
velocity in the endurance steroid-free and steroid-using
strength afthletes, compared to the reference range for differ-
ent age groups are shown in Figure 2.
Discussion
Our data indicate that both type of training and AAS
abuse may affect LV diastolic function. Although paradoxi-
cally associated with increased LA size, it appears that a
long-term AAS-free endurance training may have preferable
effects on LV filling and relaxation parameters, compared to
Table 3
Echocardiographic data on the left ventricular systolic and diastolic function
Athletes type
Parameter AAS-using strength athletes
(n = 10), ʉ ± SD
AAS-free strength athletes
(n = 10), ʉ ± SD
AAS-free endurance athletes
(n = 12), ʉ ± SD
Ejection fraction (%) 57 ± 5 59 ± 4 59 ± 4
Stroke volume (mL) 107 ± 24 112 ± 15 129 ± 17*
Cardiac output (L/min) 8.1 ± 1.7 7.6 ± 1.7 7.2 ± 1.3
Cardiac index (L/min/m
2) 3.6 ± 0.9 3.4 ± 0.7 3.4 ± 0.4
Transmitral Doppler
peak E velocity (cm/s) 84 ± 9 72 ± 15 74 ± 12
peak A velocity (cm/s) 52 ± 10
¨￿ 40 ± 10 39 ± 12
peak E/A ratio 1.7 ± 0.4 1.9 ± 0.7 2.1 ± 0.5
e wave DT (ms) 218.1 ± 36.3 233.4 ± 35.1 244.3 ± 32.2
IVRT (ms) 80 ± 8 78 ± 9 78 ± 6
TDI – septal mitral annulus
s peak (cm/s) 8.3 ± 1.3 7.9 ± 0.64 9.3 ± 1.3
†
e’ peak (cm/s) 12.1 ± 2.6 12.4 ± 2.7 13.4 ± 2.4
a’ peak (cm/s) 8.8 ± 1.4 8.6 ± 2.0 8.4 ± 1.9
E/a’ ratio 9.8 ± 1.9 8.9 ± 2.8 9.2 ± 2.5
E/e’ ratio 7.2 ± 1.4 6.0 ± 1.8 5.7 ± 0.9*
TDI – lateral mitral annulus
s peak (cm/s) 10.8 ± 2.0 9.9 ± 1.9 10.6 ± 3.5
e’ peak (cm/s) 14.8 ± 2.6 16.4 ± 2.2 19.2 ± 2.6*
†
a’ peak (cm/s) 8.7 ± 1.8 9.0 ± 1.8 8.4 ± 2.6
E/a’ ratio 10.0 ± 2.2 8.8 ± 3.6 9.4 ± 3.1
E/e’ ratio 5.2 ± 0.7 5.0 ± 1.0 3.9 ± 0.8*
†
AAS – anabolic androgenic steroids; DT – deceleration time; *significantly different from the AAS-using strength athletes (p < 0.05); †significantly
different from the AAS-free strength athletes (p < 0.05); 
¨significantly different from the AAS-free endurance athletes (p < 0.05); 
￿significantly different
from the AAS-free strength athletes (p < 0.05).
Fig. 2 – The 95% confidence intervals (CI) for the peak lateral e’ velocity in the endurance, steroid-free and steroid-using
strength athletes, compared to the reference range for different age groups. Normal values (given as 95% CI) are adopted
from the most recent guidelines 13. AAS – anabolic androgenic steroids; EA – endurance athletes; SA – strength athletes;
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strength training, particularly in the presence of AAS abuse.
No significant differences between the elite strength and en-
durance athletes were found for systolic function indices,
although mildly reduced LV ejection fraction was seen only
in AAS users.
Parameters of LV diastolic function
Reflecting the LA-LV pressure gradient during late di-
astole, mitral A-wave velocity is affected by LV compliance
and LA contractile function 
13. In line with this, a signifi-
cantly higher peak A-velocity in AAS abusers, regardless the
type of training, might indicate a relationship between AAS
misuse and decreased LV compliance.
On the other hand, peak e’ velocity, a parameter of LV
relaxation, did not significantly differ between strength ath-
letes with respect to AAS abuse. However, abnormally low
values of this parameter were observed only in the AAS
abusers – in 30% of AAS-using strength athletes (aged 27–
31 years), e’ velocities values were as low as they were meas-
ured in individuals aged between 41–60 years (Figure 2).
Although all the AAS-free athletes had normal e’ ve-
locity and E/e’ ratio values, significant differences related to
the type of training were observed. The peak e’ velocity was
higher and E/e’ ratio lower in the endurance than the strength
athletes, suggesting that strength training may not produce
equally favorable effects on diastolic function as endurance
exercise.
Mechanisms responsible for the possible alterations of
LV diastolic function with AAS abuse are poorly under-
stood. The transient increase in blood pressure, also observed
among the AAS users in this study, may negatively alter LV
diastolic function, but it is usually mild and its clinical sig-
nificance remains most likely modest 
14.
On the other hand, since no increase in LV wall thick-
ness was found, AAS-mediated changes in myocardial in-
trinsic properties might be responsible for the differences in
LV diastolic function.
Hence, in vitro and histological studies have shown that
an increase in myocardial collagen content might occur as a
repair mechanism against AAS-induced myocardial dam-
age 
15, and also that chronic administration of 17a-
methyltestosterone, frequently used anabolic steroid, may re-
duce LV compliance 
16.
Data from previous (small-scale) studies are widely in-
consistent, showing either negative 
17–20 or no effect 
21–23 of
AAS on LV diastolic function. The inconsistency could be
explained by methodological differences (pulsed-wave vs tis-
sue Doppler imaging) and by the lack of power to detect true
affects of AAS.
Relationship between LA remodeling and LV diastolic
function
In non-athletic population, dilatation of LA reflects the
cumulative effects of LV filling pressures and is an inde-
pendent predictor of death, heart failure, atrial fibrillation
and stroke 
24. Our data support the belief that LA enlarge-
ment in athletes should be regarded as a physiological adap-
tation to exercise conditioning 
25, particularly in endurance
athletes. We demonstrated that the variability of LA size was
predominantly influenced by LV dimension, but only in the
absence of AAS misuse. The correlation between the
LVEDD and LA dimension was statistically significant in
AAS-free endurance athletes and borderline significant in the
group of AAS-free strength athletes. A lack of correlation
between LA size and LVEDD in AAS-using strength athletes
may therefore be reflective of detrimental effects of AAS on
LV diastolic function, regardless of training type. In line
with this, the endurance athletes had the largest LA dimen-
sion but the lowest E/e’ ratio, suggesting that LA enlarge-
ment should not be considered pathological in these athletes.
Conversely, when LA enlargement occurs in strength ath-
letes, particularly in the presence of AAS abuse, it should not
be entirely ascribed to a long-term strength training, as it
could also reflect the disturbances of LV diastolic function.
Left ventricular remodeling, type of training and AAS
abuse
LV end-diastolic dimensions and LV mass, after being
indexed for BSA, were higher in the endurance than in the
AAS-using athletes, with no differences between the strength
athletes with respect to AAS abuse. Our data are consistent
with previous echocardiographic and magnetic resonance
imaging studies showing that long-term endurance training
has the strongest impact on LV cavity size, mass and thick-
ness while strength training does not necessarily induce wall
thickening 
18, 26, 27.
A significant increase in LV mass related to AAS ad-
ministration was observed in some studies 
20, but not con-
firmed by others 
21–23.
Left verticular systolic function
Even though we did not observe a significant difference
in LVEF among the 3 groups, a mild reduction of LVEF was
detected only in the AAS users. Results from recent studies
suggest that systolic dysfunction associated with AAS abuse
might be subclinical and advanced echo techniques are
needed for its detection 
28, 29. It has been shown that chronic
misuse of AAS is associated with reduced peak systolic
strain, and strongly correlated with mean dosage and dura-
tion of AAS use 
28. However, it has been recently reported
that, on top of reduced peak strain values, long-term AAS
use might even be associated with a clinically relevant re-
duction in LV ejection fraction 
29.
Study limitations
Our study has some important limitations. First, like
most previous studies, we did not perform plasma or urine
assessment for drug levels and the history of AAS use was
self-reported by the athletes included in the study. Although
the results should be interpreted cautiously, we believe that
the observed differences in athletes’ clinical characteristic
support the accuracy of athletes’ statements regarding AAS
use.
Both resting heart rate and diastolic blood pressure,
which increase had been previously linked to AAS abuse 
30,
were highest in the AAS-using athletes, with no differenceStrana 388 VOJNOSANITETSKI PREGLED Volumen 71, Broj 4
Iliý I, et al. Vojnosanit Pregl 2014; 71(4): 383–389.
between the AAS-denying endurance and strength athletes.
The elevation of blood pressure is usually transient, returning
to basal levels several weeks or months after drug discon-
tinuation 
31 which might explain why the AAS users had not
been diagnosed of having hypertension during regular physi-
cal examinations.
Second, since AAS abuse is a very sensitive matter in
professional sports, particularly among elite athletes, we re-
cruited a small number of subjects. However, this limitation
is more likely to produce type II errors (false-negative re-
sults) than type I errors (false-positive results) due to a re-
duced statistical power. On the other hand, type II errors
might explain why several nonsignificant trends were ob-
served – there were striking differences in mean values
among the 3 groups for several clinical and echocardio-
graphic variables, but with large variance. Therefore, further
studies with adequate power are required.
Conclusion
There is no evidence that LV ejection fraction in elite
athletes is altered by either type of training or AAS misuse.
Long-term endurance training is associated with preferable
effects on LV diastolic function compared to strength train-
ing, particularly when the latter is combined with AAS
abuse.
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